Biogen's high-stakes Alzheimer's gamble is being roasted by the experts. Is the amyloid beta theory dead?
Biogen $BIIB and its partners at Eisai had hoped to breathe some new life into the increasingly wobbly amyloid beta theory for theory for Alzheimer’s when they sounded an upbeat note about their latest data cut on BAN2401. Instead, the controversy over the trial design in the face of growing doubts about researchers’ insistence about their success has only beaten down expectations that anything can work here. And the bleak outlook is also infecting Biogen’s odds of success for their critically important program for aducanumab.
Leerink’s Geoffrey Porges led the funeral parade in a note out this morning, citing two “leading academic Alzheimer’s disease” KOLs who are backing even further away from the developers’ drugs, lowering already slim chances of success and dousing the amyloid beta theory in ways that will haunt everyone still focused on their chances here. And that’s a notable group of players.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.